Cancer Drugs Boost Antibiotic Effectiveness Against MRSA

Scientists at the University of Galway have discovered a promising link between widely used anticancer drugs and antibiotics, opening a potential new avenue for treating methicillin‑resistant *Staphylococcus aureus* (MRSA) infections. The research team focused on identifying therapeutic strategies that could overcome the growing problem of antibiotic resistance, which renders many conventional treatments ineffective against this formidable superbug.

By screening a library of anticancer compounds for activity against MRSA, the investigators found that several agents—originally designed to target rapidly dividing cancer cells—also exhibit antibacterial properties when combined with existing antibiotics. The study demonstrates that these anticancer drugs can sensitize MRSA to antibiotics that the bacteria had previously resisted, restoring their effectiveness in laboratory models. The findings suggest a repurposing strategy that could accelerate the deployment of new treatments without the lengthy development timelines typical of novel antibiotics.

If the results can be replicated in clinical settings, the approach could provide clinicians with an additional tool to combat MRSA and other resistant pathogens. The University of Galway team plans to pursue further preclinical studies to evaluate safety, dosing, and efficacy before moving toward human trials.